Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inventiva (IVA)
NASDAQ:IVA
Holding IVA?
Track your performance easily
IVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.53 - $4.75
Previous Close$2.74
Volume14.16K
Average Volume (3M)209.77K
Market Cap
$238.27M
Enterprise Value$267.07M
Total Cash (Recent Filing)€26.92M
Total Debt (Recent Filing)€54.08M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Mar 26, 2025EPS Estimate
-$1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding52,115,807
10 Day Avg. Volume15,766
30 Day Avg. Volume209,773
Standard Deviation0.17
R-Squared0.06
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-4.49
Price to Sales (P/S)4454733.61
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside200.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Inventiva News
PremiumCompany Announcements
Inventiva’s Financial Position and Future Prospects
PremiumCompany Announcements
Inventiva Reports Voting Rights and Advances Clinical Trials
PremiumCompany Announcements
Inventiva Prepares for Key General Meeting and Financing Plans
PremiumCompany Announcements
Inventiva’s Phase 2 Results Boost Hope for MASH TreatmentBulls Say, Bears Say
Bulls Say
Clinical DevelopmentLanifibranor holds significant promise as a backbone therapy in MASH with effects on both MASH resolution and fibrosis improvement, as well as across the spectrum of metabolic dysfunction.
Financial StabilityRecent financing agreement extends cash runway, providing funds for Phase 3 development, and removes an urgent and substantial financial overhang.
Market PotentialLanifibranor has shown promising Phase 2 data and could take a piece of the large MASH market.
Bears Say
Financial StabilityInventiva now faces a substantial financial overhang, with its current cash reserves sufficient in providing a cash runway to 'until mid-October 2024'.
Operational ChallengesThe next 1-2 years are seen as an execution period for the company as they await Phase 3 data.
Product ConcernsWeight gain from lanifibranor is a potential concern for physicians, despite being manageable with SGLT2 inhibitor combination.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
5.50% Other Institutional Investors
94.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $1.53 and its highest was $4.75 in the past 12 months.
What is Inventiva’s market cap?
Currently, no data Available
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Mar 26, 2025 which is in 124 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Sep 25, 2024. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.783 by -$0.017.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -$1.
How many shares outstanding does Inventiva have?
Inventiva has 87,077,700 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.783. Following the earnings report the stock price went down -17.13%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
---
Inventiva Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (200.75% Upside)
$8.00 (200.75% Upside)
Blogger Sentiment
Bullish
IVA Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.7%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-45.49%
Trailing 12-Months
Company Description
Inventiva
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis and rare diseases. All the company's operations are located in France.
---
IVA Stock 12 Month Forecast
Average Price Target
$8.00
▲(200.75% Upside)
Technical Analysis
Best Analysts Covering IVA
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-6.62%
assigned a buy rating last month
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -6.62% per trade.
---